Authorization

Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate

Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate



The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).




PVRL is a rare ocular lymphoid malignancy consisting of a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma.




ADX-2191 is designed to inhibit dihydrofolate reductase, an enzyme involved in cellular replication and activation.




Methotrexate is the most commonly used intravitreal medication for the treatment of PVRL.




Price Action: ALDX shares are up 7.18% at $9.85 during the premarket session on the last check Tuesday.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
27282930